EYPT: EyePoint Pharmaceuticals Inc

EYPT新闻

• 06:55 Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
• 06:55 Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
• 12:41 古根海姆基于Duravyu安全性数据重申EyePoint股票评级
• 12:39 Guggenheim reiterates EyePoint stock rating on Duravyu safety data
• 13:22 Mizuho维持EyePoint股票跑赢大盘评级
• 13:20 EyePoint stock rating maintained at Outperform by Mizuho
• 12:40 H.C. Wainwright将EyePoint目标价上调至30美元,看好DME试验进展
• 12:38 H.C. Wainwright raises EyePoint stock price target to $30 on DME trial progress
• 11:08 EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check (NASDAQ:EYPT)
• 22:12 EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
• 20:45 Chardan将EyePoint目标价上调至29美元,基于现金状况
• 20:43 Chardan raises EyePoint stock price target to $29 on cash position
• 13:20 EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates
• 12:14 EyePoint PharmaceuticalsQ1每股收益及营收逊于预期
• 12:14 Eyepoint Pharma earnings missed by $0.06, revenue fell short of estimates
• 04:12 EyePoint在TD Cowen会议上展示DURAVYU的市场潜力
• 04:10 EyePoint at TD Cowen Conference: DURAVYU’s Market Potential
• 19:00 Broadcom, Veeva Systems, Okta and more set to report earnings Wednesday
• 15:16 Eyepoint Pharma即将公布财报,关键试验数据在即
• 14:36 Eyepoint Pharma earnings up next as pivotal trial data looms
• 12:24 EyePoint在糖尿病性黄斑水肿三期临床试验中为首批患者给药DURAVYU